Medpace Holdings PE Ratio 2014-2023 | MEDP
Current and historical p/e ratio for Medpace Holdings (MEDP) from 2014 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Medpace Holdings PE ratio as of April 19, 2024 is 41.89.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Medpace Holdings PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2024-04-22 | 376.26 | 42.37 | |
2023-12-31 | 306.53 | $8.88 | 34.52 |
2023-09-30 | 242.13 | $8.54 | 28.35 |
2023-06-30 | 240.17 | $8.37 | 28.69 |
2023-03-31 | 188.05 | $7.90 | 23.80 |
2022-12-31 | 212.41 | $7.32 | 29.02 |
2022-09-30 | 157.17 | $6.52 | 24.11 |
2022-06-30 | 149.67 | $5.76 | 25.98 |
2022-03-31 | 163.59 | $5.36 | 30.52 |
2021-12-31 | 217.64 | $4.81 | 45.25 |
2021-09-30 | 189.28 | $4.84 | 39.11 |
2021-06-30 | 176.63 | $4.64 | 38.07 |
2021-03-31 | 164.05 | $4.22 | 38.87 |
2020-12-31 | 139.20 | $3.84 | 36.25 |
2020-09-30 | 111.75 | $3.27 | 34.17 |
2020-06-30 | 93.02 | $2.81 | 33.10 |
2020-03-31 | 73.38 | $2.90 | 25.30 |
2019-12-31 | 84.06 | $2.65 | 31.72 |
2019-09-30 | 84.04 | $2.48 | 33.89 |
2019-06-30 | 65.42 | $2.37 | 27.60 |
2019-03-31 | 58.97 | $2.09 | 28.22 |
2018-12-31 | 52.93 | $2.03 | 26.07 |
2018-09-30 | 59.91 | $1.72 | 34.83 |
2018-06-30 | 43.00 | $1.45 | 29.66 |
2018-03-31 | 34.91 | $1.23 | 28.38 |
2017-12-31 | 36.26 | $0.98 | 37.00 |
2017-09-30 | 31.90 | $0.68 | 46.91 |
2017-06-30 | 29.00 | $0.56 | 51.79 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Services | $11.526B | $1.886B |
Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Elevance Health (ELV) | United States | $123.512B | 15.50 |
Cencora (COR) | United States | $47.702B | 19.04 |
ICON (ICLR) | Ireland | $23.778B | 23.45 |
DiDi Global (DIDIY) | China | $21.472B | 0.00 |
Avantor (AVTR) | United States | $16.347B | 22.52 |
Viatris (VTRS) | United States | $13.496B | 3.85 |
CochLear (CHEOY) | $13.392B | 0.00 | |
EUROFINS SCIENT (ERFSF) | Luxembourg | $12.462B | 0.00 |
Revvity (RVTY) | United States | $12.459B | 21.69 |
Charles River Laboratories (CRL) | United States | $11.682B | 21.29 |
Solventum (SOLV) | United States | $10.730B | 0.00 |
Natera (NTRA) | United States | $10.298B | 0.00 |
Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
HealthEquity (HQY) | United States | $6.940B | 51.85 |
Bausch + Lomb (BLCO) | Canada | $5.145B | 19.78 |
Doximity (DOCS) | United States | $4.595B | 34.21 |
Organon (OGN) | United States | $4.555B | 4.41 |
PACS (PACS) | United States | $3.551B | 0.00 |
Progyny (PGNY) | United States | $3.143B | 52.74 |
Sotera Health (SHC) | United States | $3.100B | 15.21 |
Surgery Partners (SGRY) | United States | $3.017B | 28.03 |
Life Times (LTH) | United States | $2.756B | 30.46 |
GoodRx Holdings (GDRX) | United States | $2.643B | 133.80 |
Premier (PINC) | United States | $2.538B | 9.29 |
Agilon Health (AGL) | United States | $2.244B | 0.00 |
Teladoc Health (TDOC) | United States | $2.198B | 0.00 |
AMN Healthcare Services Inc (AMN) | United States | $2.158B | 6.98 |
BrightSpring Health Services (BTSG) | United States | $1.799B | 0.00 |
Agiliti (AGTI) | United States | $1.366B | 22.31 |
Establishment Labs Holdings (ESTA) | $1.301B | 0.00 | |
NovoCure (NVCR) | Jersey | $1.301B | 0.00 |
Alignment Healthcare (ALHC) | United States | $0.983B | 0.00 |
Pediatrix Medical (MD) | United States | $0.759B | 7.85 |
Embecta (EMBC) | United States | $0.611B | 4.04 |
InnovAge Holding (INNV) | United States | $0.537B | 0.00 |
COMPASS Pathways (CMPS) | United Kingdom | $0.519B | 0.00 |
Enhabit (EHAB) | United States | $0.514B | 46.59 |
Auna S.A (AUNA) | Luxembourg | $0.503B | 0.00 |
CareDx (CDNA) | United States | $0.430B | 0.00 |
MultiPlan (MPLN) | United States | $0.419B | 0.00 |
Beauty Health (SKIN) | United States | $0.404B | 0.00 |
LifeMD (LFMD) | United States | $0.392B | 0.00 |
Sonida Senior Living (SNDA) | United States | $0.388B | 0.00 |
DocGo (DCGO) | United States | $0.372B | 59.50 |
Sera Prognostics (SERA) | United States | $0.316B | 0.00 |
ModivCare (MODV) | United States | $0.302B | 4.00 |
Ascend Wellness Holdings (AAWH) | United States | $0.263B | 0.00 |
GeneDx Holdings (WGS) | United States | $0.251B | 0.00 |
Sharecare (SHCR) | United States | $0.235B | 0.00 |
Biodesix (BDSX) | United States | $0.121B | 0.00 |
So-Young (SY) | China | $0.115B | 38.67 |
Oncology Institute (TOI) | United States | $0.088B | 0.00 |
Pono Capital Two (PTWO) | United States | $0.064B | 0.00 |
IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
NeueHealth (NEUE) | United States | $0.048B | 0.00 |
Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
Nutex Health (NUTX) | United States | $0.035B | 0.00 |
NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
Singular Genomics Systems (OMIC) | United States | $0.029B | 0.00 |
SeaStar Medical Holding (ICU) | United States | $0.022B | 0.00 |
DermTech (DMTK) | United States | $0.022B | 0.00 |
OncoCyte (OCX) | United States | $0.021B | 0.00 |
BIMI Holdings (BIMI) | United States | $0.015B | 0.00 |
Aesthetic Medical Hldngs Group (AIH) | China | $0.012B | 0.00 |
BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
OpGen (OPGN) | United States | $0.008B | 0.00 |
Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
XWELL (XWEL) | United States | $0.006B | 0.00 |
Assure Holdings (IONM) | United States | $0.003B | 0.00 |
NewGenIvf Group (NIVF) | Singapore | $0.003B | 0.00 |
ISpecimen (ISPC) | United States | $0.003B | 0.00 |
Aclarion (ACON) | United States | $0.002B | 0.00 |